Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators

Area of Science:

• Genetics and Molecular Biology
• Pulmonology
• Pharmacology

Background:

• Cystic fibrosis (CF) is a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
• CFTR protein dysfunction leads to a severe autosomal recessive disorder affecting epithelial cells.
• CFTR modulators offer new treatment avenues by restoring protein function.

Purpose of the Study:

• To review current and emerging therapeutic strategies for cystic fibrosis patients with mutations ineligible for existing CFTR modulators.
• To explore approaches for expanding CFTR modulator eligibility to rare genotypes.
• To discuss novel therapies for CFTR mutations that prevent protein production.

Main Methods:

• Review of pre-clinical and early clinical research on CFTR modulator development and alternative therapeutic strategies.
• Analysis of approaches including readthrough agents, nucleic acid-based therapies, and cell-based therapies.
• Evaluation of methods for assessing drug efficacy in rare CFTR mutation populations.

Main Results:

• CFTR modulators show promise but do not benefit all CF patients, particularly those with rare or null mutations.
• Several innovative therapies are under investigation, including readthrough agents for nonsense mutations and nucleic acid-based treatments.
• These advanced therapies are primarily in pre-clinical or early clinical development stages.

Conclusions:

• Significant challenges remain in translating novel CFTR therapies from research to clinical practice.
• Developing mutation-specific and mutation-agnostic therapies is crucial for treating the full spectrum of cystic fibrosis.
• Continued research and strategic drug evaluation are essential for advancing cystic fibrosis care.